Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|December 3, 2020

Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines

***Live: Thursday, Dec. 3, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET*** Review preclinical strategies to improve drug development outcomes for biologic drugs, including innovative solutions and risk-based approach to expedite investigational new drug submissions, especially for pandemic response initiatives.. ***On demand available after final airing until Dec. 3, 2021***

Register Free: https://www.biopharminternational.com/bp_w/strategies

Event Overview:

Sponsors developing innovative biologic therapies face key challenges to bring their compound to the clinic quickly. An investigational new drug (IND) submission is a key milestone for every drug development program. This webinar will discuss the best practices to expedite biologics drug candidates quickly from discovery to IND submission including safety assessment and chemistry, manufacturing, and controls (CMC) programs with real-world case studies, including how the CMC development timelines were adapted to expedite COVID-19 therapeutics into clinical trials.

Key Learning Objectives:

  • Key considerations for developing and manufacturing of biologics drug
  • Comprehensive preclinical strategies to improve drug development outcomes
  • Innovative solutions and risk-based approach to expedite IND submissions, especially for pandemic response initiatives
  • Strategies to save significant time and money to help meet IND submission and early-phase clinical trial goals and milestones

Speakers:

Xuejun (Sherry) Gu, PhD, Vice President, CMC Management (US), WuXi Biologics

Jing Shi, PhD, Executive Director and Global Head of Large Molecule Bioanalytical Services, WuXi AppTec Laboratory Testing Division

Time and Date: Thursday, December 3, 2020 at 11am EST| 8am PST| 4pm GMT| 5pm CET

On Demand Until Dec. 3 2021

Register Free: https://www.biopharminternational.com/bp_w/strategies


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.